Skip to main content
. 2022 Mar;76(3):549–557. doi: 10.1016/j.jhep.2021.09.038

Table 1.

Characteristics of the PWID cohort achieving SVR in Scotland by time of initiating treatment for HCV.

2000-2009 (col %) 2010-2014 (col %) 2015-2016 (col %) 2017-2018 (col %)
Total PWID achieving SVR 886 1,587 1,426 1,787
NHS board of treatment
 Greater Glasgow and Clyde 410 (46.3) 863 (54.4) 854 (59.9) 1,102 (61.7)
 Grampian/Lothian 331 (37.4) 421 (26.5) 346 (24.3) 341 (19.1)
 Tayside 145 (16.4) 303 (19.1) 226 (15.8) 344 (19.3)
Treatment setting
 Hospital 206 (23.3) 1,109 (69.9) 1,059 (74.3) 983 (55.0)
 Community 7 (0.8) 227 (14.3) 259 (18.2) 682 (38.2)
 Prison 11 (1.2) 125 (7.9) 105 (7.4) 122 (6.8)
 Other/not known∗∗ 662 (74.7) 126 (7.9) 3 (0.2) 0 (0.0)
Sex
 Female 235 (26.5) 349 (22.0) 319 (22.4) 452 (25.3)
 Male 651 (73.5) 1,238 (78.0) 1,107 (77.6) 1,335 (74.7)
Age (years)
 50+ 86 (9.7) 227 (14.3) 438 (30.7) 467 (26.1)
 35-49 498 (56.2) 884 (55.7) 806 (56.5) 1,098 (61.4)
 <35 302 (34.1) 476 (30.0) 182 (12.8) 222 (12.4)
Treatment regimen
 Interferon-based 882 (99.5) 1,522 (95.9) 444 (31.1) 28 (1.6)
 Interferon-free 0 (0.0) 57 (3.6) 982 (68.9) 1,759 (98.4)
 Other/not known 4 (0.5) 8 (0.5) 0 (0.0) 0 (0.0)
Cirrhosis at time of treatment
 No 820 (92.6) 1,291 (81.3) 971 (68.1) 1,462 (81.8)
 Yes 66 (7.4) 296 (18.7) 455 (31.9) 325 (18.2)
Opioid/injection hospital admission
 >3 years pre-treatment/never pre-Treatment 771 (87.0) 1,285 (81.0) 1,124 (78.8) 1,272 (71.2)
 During treatment/in the 3 years pre-treatment 115 (13.0) 302 (19.0) 302 (21.2) 515 (28.8)

NHS, National Health Service; PWID, people who inject drugs; SVR, sustained virological response.

Achieved SVR according to the Scottish HCV clinical database. Patients can achieve SVR more than once if they were reinfected.

∗∗

Whilst treatment setting was not recorded on the clinical database during 2000-2009, the vast majority would have been hospital.